Other therapy.

Constructive Technology Assessment (CTA) as a Tool in Coverage with Evidence Development: The Case of the 70-gene Prognosis Signature for Breast Cancer Diagnostics

PUBLICATION: Int J Technol Assess Health Care. 2009 Jan;25(1):73-83. doi: Read More

2024-03-25T11:11:06-04:00January 24th, 2009|Evidence, MammaPrint, Other|

Robust Interlaboratory Reproducibility of a Gene Expression Signature Measurement Consistent with the Needs of a New Generation of Diagnostic Tools

PUBLICATION: BMC Genomics. 2007 Jun 7;8:148. AUTHORS: Ach R.A., Floore Read More

2024-03-25T11:15:05-04:00June 7th, 2007|Evidence, MammaPrint, Other, Validation|

Gene Expression Profiles of Primary Breast Carcinomas from Patients at High-Risk for Local Recurrence After Breast-Conserving Therapy

PUBLICATION: Clin Cancer Res. 2006 Oct 1;12(19):5705-12. AUTHORS: Kreike B., Read More

2024-03-25T11:17:36-04:00October 1st, 2006|Evidence, MammaPrint, Other|

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women with Node-Negative Breast Cancer

PUBLICATION: J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92. AUTHORS: Buyse Read More

2024-03-25T11:18:22-04:00September 6th, 2006|Evidence, MammaPrint, Other, Validation|

Molecular Portraits and 70-gene Prognosis Signature Are Preserved Throughout the Metastatic Process of Breast Cancer

PUBLICATION: Cancer Res. 2005 Oct 15;65(20):9155-8. AUTHORS: Weigelt B., Hu Read More

2024-03-25T11:19:17-04:00October 5th, 2005|Evidence, MammaPrint, Other, Validation|
Go to Top